Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ: ESPR )

1.500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Why Is Esperion Therapeutics (ESPR) Stock Down 60% Today?
Esperion Therapeutics (ESPR) stock is taking a beating on Thursday as the company comes into conflict with Daiichi Sankyo Europe. 
Via InvestorPlace
Netflix To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for LyondellBasell Industries N.V. (NYSE: LYB) from $85 to $74. Keybanc analyst Aleksey Yefremov maintained an Underweight rating. LyondellBasell shares fell 3.7% to close... 
Via Benzinga
Why UiPath Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) rose 38.9% to $5.82 in pre-market trading. ThermoGenesis shares jumped around 99% on Wednesday after the company announced the roll out of ReadyStart... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers as we go over all the latest news for Thursday morning! 
Via InvestorPlace
The Latest Analyst Ratings for Esperion Therapeutics
Via Benzinga
Looking Into Esperion Therapeutics's Return On Capital Employed
Via Benzinga
LivePerson, Amyris And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
Esperion Therapeutics's Earnings Outlook
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at... 
Via Benzinga
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P... 
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500... 
Via Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose... 
Via Benzinga
Esperion Therapeutics Stock Is Diving: What's Going On?
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. 
Via Benzinga
Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors
Via Benzinga
Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Launches New Scientific Website
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CLEAR Outcomes Company Update Call: Detailed Results Discussion
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.